Orexo AB (FRA:C5G) E10: €-0.19 (As of Mar. 2026)


FRA:C5G Orexo AB FRA:C5G
43 GF Score
Price €2.10
GF Value €0.55
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Orexo AB E10?

Orexo AB FRA:C5G +5.49% 43 E10 is €-0.19 as of Mar. 2026. GuruFocus rates FRA:C5G with a GF Score™ of 43/100 and a GF Value™ of €0.55 (Significantly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Orexo AB's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.354. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-0.19 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average E10 Growth Rate was -2.40% per year. During the past 5 years, the average E10 Growth Rate was -0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Orexo AB was 25.90% per year. The lowest was -13.40% per year. And the median was 12.60% per year.

As of today (2026-06-29), Orexo AB's current stock price is €2.095. Orexo AB's E10 for the quarter that ended in Mar. 2026 was €-0.19. Orexo AB's Shiller PE Ratio of today is .


Orexo AB  (FRA:C5G) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Orexo AB E10 Related Terms


Orexo AB E10 Historical Data

* Premium members only.

The historical data trend for Orexo AB's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orexo AB E10 Chart

Orexo AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.13 -0.16 -0.14 -0.18 -0.17

Orexo AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.18 -0.15 -0.15 -0.17 -0.19

FRA:C5G vs ZTS, UTHR: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orexo AB's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orexo AB Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orexo AB's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Orexo AB's Shiller PE Ratio falls into.


FRA:C5G
43GF Score
Orexo AB FRA:C5G
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orexo AB E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Orexo AB's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.354/133.3862*133.3862
=-0.354

Current CPI (Mar. 2026) = 133.3862.

Orexo AB Quarterly Data

per share eps CPI Adj_EPS
201606 0.015 101.019 0.020
201609 0.109 101.138 0.144
201612 0.099 102.022 0.129
201703 -0.105 102.022 -0.137
201706 0.009 102.752 0.012
201709 0.085 103.279 0.110
201712 0.078 103.793 0.100
201803 -0.074 103.962 -0.095
201806 0.141 104.875 0.179
201809 0.170 105.679 0.215
201812 0.143 105.912 0.180
201903 0.038 105.886 0.048
201906 0.142 106.742 0.177
201909 0.296 107.214 0.368
201912 0.105 107.766 0.130
202003 0.215 106.563 0.269
202006 -0.090 107.498 -0.112
202009 -0.235 107.635 -0.291
202012 -0.143 108.296 -0.176
202103 -0.090 108.360 -0.111
202106 -0.213 108.928 -0.261
202109 -0.148 110.338 -0.179
202112 -0.187 112.486 -0.222
202203 -0.065 114.825 -0.076
202206 -0.098 118.384 -0.110
202209 -0.071 122.296 -0.077
202212 -0.243 126.365 -0.257
202303 -0.166 127.042 -0.174
202306 -0.032 129.407 -0.033
202309 -0.082 130.224 -0.084
202312 -0.048 131.912 -0.049
202403 -0.023 132.205 -0.023
202406 -0.092 132.716 -0.092
202409 -0.107 132.304 -0.108
202412 -0.448 132.987 -0.449
202503 -0.042 132.825 -0.042
202506 -0.104 133.699 -0.104
202509 -0.078 133.482 -0.078
202512 -0.306 133.386 -0.306
202603 -0.354 133.386 -0.354

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-0.19 mean?
Orexo AB (FRA:C5G) has a E10 of €-0.19 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Orexo AB and its competitors.
Is Orexo AB's E10 too high?
Orexo AB's current E10 is €-0.19. Overall, Orexo AB has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orexo AB's E10 compare to ZTS and UTHR?
Orexo AB's E10 of €-0.19 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Orexo AB and its competitors. Orexo AB's current E10 is €-0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orexo AB stock overvalued right now?
Based on GuruFocus' analysis, Orexo AB (FRA:C5G) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.55, compared to a current price of €2.10 — trading 280.9% above its estimated fair value. The current E10 is €-0.19. Orexo AB's overall GF Score™ is 43/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Orexo AB (FRA:C5G), the current E10 is €-0.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Orexo AB (FRA:C5G) Overvalued in 2026?

Based on GuruFocus' analysis, Orexo AB stock appears to be overvalued. The current stock price of €2.10 is trading 280.9% above its estimated GF Value™ of €0.55. GuruFocus considers Orexo AB to be Significantly Overvalued.

Key valuation signals for FRA:C5G:

  • E10: €-0.19
  • GF Value™: €0.55 vs. price of €2.10 (280.9% above fair value)
  • GF Score™: 43/100 with 8 warning signs

No single metric tells the full story. See the FRA:C5G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orexo AB Business Description

Address Virdings alle 22, Uppsala, SWE, 75105
Orexo AB is a Swedish pharmaceutical company dedicated to advancing treatments for severe diseases and life-saving rescue medications to meet future healthcare needs, developing improved medications based on proprietary drug delivery technologies. At the core of its innovation is AmorphOX, which improves bioavailability and stability for both large and small molecules. It has developed four drugs from concept to approval, including Zubsolv, Abstral, Edluar, and Diabact UBT. The company's current development efforts focus on AmorphOX, with projects in preclinical and clinical phases across multiple therapeutic areas. It operates through US Commercial and HQ & Pipeline, which generate maximum revenue, and operates in the US, EU, and UK generating maximum revenue, and the Rest of the World.
43GF Score

Get the complete analysis for FRA:C5G

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.10
Price
€0.55
GF Value